Breaking News
February 18, 2019 - New dental adhesive prevents tooth decay around orthodontic brackets
February 18, 2019 - New eHealth tool shows potential to improve quality of asthma care
February 18, 2019 - New Australian initiative helps emergency clinicians to improve patient care
February 17, 2019 - Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
February 17, 2019 - Researchers identify faulty ‘brake’ that interferes with heart muscle’s ability to contract and relax
February 17, 2019 - Support from trusted adults can reduce risk of dying in suicidal teens, finds study
February 17, 2019 - Heart attack awareness improved since 2008
February 17, 2019 - Exercise gives a better brain boost to older men than women
February 17, 2019 - New research disproves previous assumptions of how looks influence personality
February 17, 2019 - Cannabis use as a teenager linked to depression later in life
February 17, 2019 - Sinks by Toilets in ICU Patient Rooms Harbor Harmful Bacteria
February 17, 2019 - Cancer cells’ plasticity makes them harder to stop
February 17, 2019 - Young cannabis users have increased risk of depression and suicidal behavior
February 17, 2019 - Tasmanian Devils Likely to Survive Cancer Scourge
February 17, 2019 - Neoadjuvant PD-1 blockade seems effective in glioblastoma
February 17, 2019 - Personal, social factors play role in enabling sustainable return to work after ill health
February 17, 2019 - Mouse studies show ‘inhibition’ theory of autism wrong
February 17, 2019 - Study shows how neuroactive steroids inhibit activity of pro-inflammatory proteins
February 17, 2019 - Use of liver grafts from older donors decreased despite better outcomes in recipients
February 17, 2019 - MUSC researchers discover new mechanism for a class of anti-cancer drugs
February 17, 2019 - HPV misconceptions are causing women to miss smear tests
February 17, 2019 - Sanofi and Regeneron Offer Praluent (alirocumab) at a New Reduced U.S. List Price
February 17, 2019 - Researchers say auditory testing can identify children for autism screening
February 17, 2019 - New method analyzes how single biological cells react to stressful situations
February 17, 2019 - WVU gynecologic oncologist investigates novel treatment for cervical and vaginal cancers
February 17, 2019 - ADHD diagnoses poorly documented
February 17, 2019 - Majority of gender minority youth do not identify with traditional sexual identity labels
February 17, 2019 - AbbVie, Teneobio enter into strategic transaction to develop potential treatment for multiple myeloma
February 17, 2019 - Lower Birth Weight May Up Risk for Psychiatric Disorders
February 17, 2019 - Scientists identify reversible molecular defect underlying rheumatoid arthritis
February 17, 2019 - Moffitt researchers shed light on how CAR T cells function mechanistically
February 16, 2019 - Female Anatomy May Play Big Role in Sperm’s Success
February 16, 2019 - BMI may mediate inverse link between fiber intake, knee OA
February 16, 2019 - Movement impairments in autism can be reversed through behavioral training
February 16, 2019 - Studies address racial disparities in postpartum period and cardiovascular health
February 16, 2019 - Scientists implicate hidden genes in the severity of autism symptoms
February 16, 2019 - Decreased deep sleep linked to early signs of Alzheimer’s disease
February 16, 2019 - Neuroscientists show how the brain responds to texture
February 16, 2019 - Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
February 16, 2019 - What Can I Do About Sweating? (for Teens)
February 16, 2019 - Companies navigate dementia conversations with older workers
February 16, 2019 - Newly developed stem cell technologies show promise for treating PD patients
February 16, 2019 - Collaborative material research could advance self-assembling nanomaterials
February 16, 2019 - Researchers take major step in creating technology that mimics the human brain
February 16, 2019 - Erasing memories associated with cocaine use reduces drug seeking behavior
February 16, 2019 - Artificial intelligence can accurately predict prognosis of ovarian cancer patients
February 16, 2019 - Racial disparities in cancer deaths on the decline for America
February 16, 2019 - FDA authorizes new interoperable insulin pump for children, adults with diabetes
February 16, 2019 - Coexisting Medical Conditions, Smoking Explain PTSD-CVD Link
February 16, 2019 - Skin Cancer Screening: MedlinePlus Lab Test Information
February 16, 2019 - ‘Happiness’ exercises can boost mood in those recovering from substance use disorder
February 16, 2019 - Cell manipulation could soon halt or reverse aging
February 16, 2019 - Pumped Breast Milk Falls Short of Breastfed Version
February 16, 2019 - Men’s porn habits could fuel partners’ eating disorders, study suggests
February 16, 2019 - Rapid progression of age-related diseases may result from formation of vicious cycles
February 16, 2019 - Immune checkpoint molecule protects against future development of cancer
February 16, 2019 - New method produces hydrogels that have properties similar to cells’ environment
February 16, 2019 - $4.1 million funding for heart research on Valentine’s Day
February 16, 2019 - General anesthesia in early infancy unlikely to have lasting effects on developing brains
February 16, 2019 - New breakthroughs for muscular dystrophy research
February 16, 2019 - First Opinion: Embryo editing for higher IQ is a fantasy. Embryo profiling for it is almost here
February 16, 2019 - Vapers develop cancer-related gene deregulation as cigarette smokers
February 16, 2019 - Bringing Antimicrobial Susceptibility Testing (AST) to the Community
February 16, 2019 - Decolonization protocol after hospital discharge can prevent dangerous infections
February 16, 2019 - Children with ASD more likely to face maltreatment, study finds
February 16, 2019 - Study finds genetic vulnerability to use of menthol cigarettes
February 16, 2019 - Promising drug developed to rejuvenate muscle cells
February 16, 2019 - H-RT should be the standard of care for men with low risk prostate cancer, study shows
February 16, 2019 - New technique using patients’ own modified cells could help treat Crohn’s disease
February 16, 2019 - Therapeutic endoscopy has an expanding role in the treatment of IBD
February 16, 2019 - Blood clot discovery could lead to development of better treatments for blood diseases
February 16, 2019 - Intervention can increase exclusive breastfeeding rates
February 16, 2019 - New project explores how gaming technologies can help cancer patients communicate better
February 16, 2019 - Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
February 16, 2019 - Rerouting nerves during amputation reduces phantom limb pain before it starts
February 16, 2019 - A Hormone Produced When We Exercise Might Help Fight Alzheimer’s
February 16, 2019 - Millions of British people breathe toxic air travelling to GPs
February 16, 2019 - Conformance of genetic characteristics found to be crucial for longer preservation of kidney graft
February 16, 2019 - Researchers use optogenetic tool to control, visualize receptor signals in neural cells
February 16, 2019 - New reversible antiplatelet therapy could reduce risk of blood clots, prevent cancer metastasis
Gyn Cancer Research Gets Short Shrift in Funding

Gyn Cancer Research Gets Short Shrift in Funding

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

NEW ORLEANS — Federal funding for medical research severely short changes gynecologic oncology when cancer lethality is taken into account, according to data presented here.

Among 13 common cancers included in the analysis, gynecologic cancers ranked near the bottom in funding support, as determined by federal spending per years of life lost for each type of cancer. Three gynecologic cancers used for the analysis — ovarian, cervical, and uterine — landed near the bottom of the list individually and collectively.

A comparison of ovarian and prostate cancer, for example, showed a mean expenditure of $85,000 per years of life lost (YLL) per 100 new cases of ovarian cancer. The mean soared beyond $1 million for prostate cancer. Even greater disparities resulted from analyses involving cervical and uterine cancer, Ryan Spencer, MD, of the University of Wisconsin in Madison, reported at the Society of Gynecologic Oncology (SGO) meeting.

“We observed that gynecologic cancers are disproportionately underfunded compared to most other cancer sites when using the funding-to-lethality score to standardize the impact of mortality, incidence, and person years of life lost to cancer death across various cancer sites,” said Spencer. “These disparities are seen when the data are aggregated and when the data are re-analyzed by individual year and when year-over-year trends are explored.

“Given current funding projections and the decline in clinical trial availability, these trends are likely to continue to worsen, rather than improve.”

SGO invited discussant Paola Gehrig, MD, of the University of North Carolina at Chapel Hill, noted that federal funding for clinical trials in all types of cancer has declined substantially in recent years. For example, the NCI funded 27% of new research proposals in 2001, but that declined to 12% by 2015. From 2008 to 2017, the number of fully funded NIH studies presented at the American Society of Clinical Oncology meeting decreased by 75%.

However, outcomes in at least some gynecologic cancers have not improved to the same degree as some common cancers during the decline in federal funding. Using her specialty of uterine cancer as an example, Gehrig noted that disease-specific mortality for uterine cancer increased 2% annually from 2010 to 2014.

Borrowing a statement from Spencer’s presentation, Gehrig concluded, “Without a correction, gynecologic cancers will continue to be underfunded and risk lagging behind other cancer sites in critical discoveries for cure and life prolongation, in this important era of immunotherapy, molecular targeting, and personalized medicine.”

The study had its origin in what Spencer described as a crisis in enrollment in gynecologic cancer clinical trials. From 2011 to 2016, enrollment in gyn cancer trials decreased by 90%, and the number of available trials declined by 68%. The objective was to determine the equability of NCI funding distributions across different types of cancer.

Data for the analyses came from the NCI Surveillance, Epidemiology, and End Results registry program and the Cancer Trends Progress Report and funding statistics for the years 2007-2014.

Investigators calculated a “funding-to-lethality” score for uterine, ovarian, and cervical cancer, as well as for 10 other types of cancer. The comparators included a mix of common diseases (breast, lung, prostate, colon), cancers with incidences similar to the gyn cancers, and cancers that affect only men (prostate, testicular).

To achieve a balance among cancer incidence, mortality, and burden of YLL, investigators determined YLL for each of the 13 cancers included in the analysis and then used federal funding for each of the cancers to calculate funding-to-lethality values.

In the overall analysis, prostate and breast cancer came out far ahead of all the other types of cancer. From 2007-2014, prostate cancer had a funding-to-lethality score of 1.811, which translated into $1,811,000 per YLL per 100 new cases. Breast cancer followed close behind with a score of 1.803 and $1,803,000 per YLL per 100 cases. Ovarian cancer ranked 9th (0.97, $97,000), cervical cancer ranked 10th (0.87, $87,000), and uterine cancer ranked 12th (0.057, $57,000). Testicular cancer came in last (0.044, $44,000).

Using the data for 2014, Spencer’s group compared ovarian and prostate cancers. Ovarian cancer had a mortality of 7.0191 deaths/100,000, versus 19.1189/100,000 for prostate cancer, and an incidence of 11,3496/100,000 versus 99.6716/100,000. Dividing mortality by incidence resulted in 0.618 deaths per new cancer for ovarian cancer and 0.192 for prostate cancer.

Multiplying the deaths per new cancer by 17.5 years of life lost to death by ovarian cancer and 9.9 years of life lost with each prostate cancer death yielded 1,282 YLL per 100 new cases of ovarian cancer and 189.9 YLL/100 for prostate cancer.

Finally, investigators divided the $91.5 million in funding by the YLL to arrive at $85,000/YLL/100 new cases and a funding-to-lethality score of 0.085 for ovarian cancer. The same calculations with $217.8 million in funding for prostate cancer resulted in $1,147,000 per YLL/100 and a funding-to-lethality score of 1.15.

Across the entire study period, the funding-to-lethality scores and funding per YLL per 100 new cases for the other cancers were:

  • Melanoma: -0.519 and $519,000
  • Colorectal: -0.422 and $442,000
  • Lung: -0.3 and $363,000
  • Leukemia: -0.353 and $353,000
  • Non-Hodgkin’s lymphoma: -0.284 and $284,000
  • Kidney: -0.112 and $112,000
  • Pancreas: -0.074 and $74,000

Spencer acknowledged several limitations of the study. The analysis did not account for funding from sources other than NCI. Funding gaps are likely multifactorial. A “correct” or “appropriate” funding-to-lethality score has not been determined.

Spencer and colleagues disclosed no relevant relationships with industry.

1969-12-31T19:00:00-0500

last updated

Tagged with:

About author

Related Articles